Anufacturing And Control Cmc Data These Requests Could Not Be Reasonably Delivered Within The Prescribed Review Timeframe Company Is Assessing Alternative Regulatory Options Available For Most Streamlined Route To Approval Witha Revised Submission Will Provide An Update On Anticipated Timings When This Assessment Has Been Completed Subsequent Quarter 14 October 2022 News Today : Breaking News, Live Updates & Top Stories | Vimarsana
MELBOURNE, Australia, Oct. 20, 2022 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 30 September 2022 (Q3 2022). All figures are in AUD$ unless otherwise stated.[1] All figures are provided on an unaudited basis. Financial Summary Telix reports total revenue of $55.3 million from global sales of Illuccix, up 168% on the previous quarter ($20.6 million, Q2 2022) U.S. sales of Illuccix up 178% to $53.7 million (US$36.4 million) in second quarter of commercial sales ($19.3 million, Q2 2022) Cash balance of $117.1 million; provides 21 quarters of cash runway (based on Q3 2022 burn rate) Net operating cash outflow reduced by $20.5 million to $5.3 million, a significant reduction on the prior quarter ($25.8 million net operating cash outflow). Key factors impacting this improvement are: Customer receipts of $44.5 million, up from $5.4 million in the p